AUA 2017Aligning around what’s best for the patient
The upcoming AUA annual meeting is always one of the most exciting of the year for us. Coming off of an engaging, aligning 2017 edition of the American Brachytherapy Society annual meeting, AUA 2017 will be especially interesting, as it will feature some of the latest information on two key areas of prostate cancer treatment:
- The use of different modalities for the targeted treatment of localized, low volume prostate cancer; and
- The different strategies for the treatment of higher risk localized treatment, including the incorporation of brachytherapy into the treatment regimen. We will be paying close attention to the associated plenary sessions on Friday, May 12 between 11:00 a.m and 11:30 a.m. You can find the full conference program and schedule here.
AUA 2017 is expected to have the latest information of patient quality of life following brachytherapy. Will also be interested to see how leading urologists address the updated draft USPSTF recommendations on prostate cancer screening.
Screening offers a small potential benefit of reducing the chance of dying of prostate cancer. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; over-diagnosis and over-treatment; and treatment complications, such as incontinence and impotence. The USPSTF recommends individualized decision-making about screening for prostate cancer after discussion with a clinician, so that each man has an opportunity to understand the potential benefits and harms of screening and to incorporate his values and preferences into his decision.
Brachytherapy is a value-based treatment for prostate cancer
Brachytherapy has suffered a decrease in utility for prostate cancer treatments in the past several years. This is particularly disturbing given the available scientific data that indicates brachytherapy is a value-based course of treatment that improves outcomes (including quality of life) and reduces overall costs in prostate cancer care. We aim to help change this to the benefit of tens of thousands of men with prostate cancer.
At Isoray, we intend to provide the entirety of the prostate cancer care continuum with the information required to make truly patient-centric treatment decisions. This includes close collaboration with our colleagues like Dr. Ron Benoit, MD, Urologist with the University of Pittsburgh Medical Center.
“Surgeons and urologists tend to be the first to diagnose prostate cancer,” said Dr. Benoit. “They’re seeing patients first, they want to help patients, they’re trained to operate, so that’s where they go. They feel very strongly that they help patients with surgery, so they offer surgery.
“We need to lower healthcare costs in this country. When payers are told about the benefits of brachytherapy and realize that treatment costs are much lower than surgery and external beam radiation, and the outcomes are just as good if not better in terms of both cancer control and side effects, that’s when the needle will move in terms of a big change. I think it’s the payers who are going to start pushing providers to do brachytherapy, or explain why they’re not.”
Read more from our story with Dr. Benoit on breaking barriers in successfully treating prostate cancer with brachytherapy here.
Our Patient’s Stories
Connect with Isoray at AUA
Connect with the Isoray team at AUA 2017 to learn about Cesium brachytherapy’s ability to improve patient outcomes while reducing costs by visiting booth #438. To schedule a meeting time in advance, contact Isoray’s Bill Gallien via email: firstname.lastname@example.org
Still Going Strong After 15,000 Cases: Chicago Prostate Cancer Center Focuses on What is Best for the Patient
“I am a huge believer in Brachytherapy. It is the best option in treating prostate cancer.”Dr. Steven Kurtzman, MD
“Perminent Interstitial Brachytherapy with Cesium-131 should atleast be considered for any woman presented with a local recurrence of gynecological cancer.”Dr. Jonathan Feddock, MD